生命科学资讯

Rethinking heart attacks as nervous system gone haywire sparks potential new drug targets

TD Cowen picks top 3 medtech prospects across its ‘Bones, Bots, and No More Shots’ portfolio

Cardiff execs depart as company drops mixed Phase 2 data

UnitedHealth projects lower revenue in 2026 as it resets its business

Appointments and advancements for Jan. 27, 2026

Financings for Jan. 27, 2026

In the clinic for Jan. 27, 2026

Other news to note for Jan. 27, 2026

Regulatory actions for Jan. 27, 2026

FDA lifts hold on an Intellia CRISPR drug trial

Roche, trailing in obesity, showcases new data for GLP-1 shot

'AI-native' outpatient surgery startup Oath Surgical inks Nvidia partnership

United Therapeutics' bioengineered temporary liver shows promise in phase 1 trial

From gene therapies to … firearms? Italian biotech makes unexpected strategic pivot

Lisata reclaims China rights to solid tumor candidate ahead of acquisition

After patient death, FDA lifts hold on 1 of 2 late-stage trials testing Intellia’s CRISPR therapy

An immune drug developer raises $50M to finance its eczema drug testing

FDA lifts hold on one of two Phase 3 gene editing studies by Intellia

Insilico’s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma

AstraZeneca ends work on cardio drug; Lisata and Qilu terminate deal